DOCSLIB.ORG

BICALUTAMIDE -- Withdrawn Due to Accelerated Deaths

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BICALUTAMIDE -- Withdrawn Due to Accelerated Deaths No. 5, 2003 EDITORIAL We are pleased to report that the first meeting of the newly established Advisory Committee on Safety of Medicinal Products was held in October. This meeting was very productive and a number of recommendations as published in this issue were made. A statement was made by this Committee recommending the need to incorporate pharmacovigilance in the WHO strategy to provide antiretrovirals to three million people by 2005. The feature article emphasizes the urgency in evolving a safety strategy for herbal issues as these remain largely un-addressed. Representatives from WHO attended the International Contents Conference on Harmonization (ICH) expert working group meetings in November, in Osaka, as observers. The document Regulatory matters Pharmacovigilance Planning, which describes the link between Safety of medicines pre- and post-marketing surveillance will now be circulated to Member States for comments. The 26th Annual Meeting of Drugs of interest the National Centres participating in the International Drug Feature Monitoring Programme will be held in December, in India. The meeting will focus on ADR reporting and how it can be Miscellany improved. A detailed report of this meeting will appear in one of the later issues. TABLE OF CONTENTS REGULATORY MATTERS ASTEMIZOLE -- Withdrawn due to ventricular arrhythmias ...................................................... 1 BICALUTAMIDE -- Withdrawn due to accelerated deaths.......................................................... 1 DACLIZUMAB -- Warning about hypersensitivity reactions, increased mortality in cardiac transplant study ................................................................................... 1 DANAZOL -- Use restricted to second line therapy in endometriosis .......................................... 1 LEVACETYLMETHADOL -- Product to be withdrawn due to adverse cardiac events; safer alternatives to be adopted.............................................................................. 2 MOROCTOCOG ALFA -- Reports of lack of effect in prophylaxis patients..................................... 2 NEFAZODONE -- Sale discontinued due to adverse hepatic events ............................................ 2 NIMESULIDE -- Product under ‘special pharmacovigilance’....................................................... 2 OSELTAMIVIR -- Adverse reactions section to include acute renal failure, thrombocytopenia, leukopenia ........................................................................................... 3 PHENYLPROPANOLAMINE -- New warnings on cardiovascular risks to be added .......................... 3 SOMATROPIN -- Refused approval for use in AIDS-related wasting syndrome ............................ 3 TERFENADINE -- Withdrawn due to ventricular arrhythmias..................................................... 3 VALSARTAN -- Reports of interstitial pneumonia..................................................................... 3 SAFETY OF MEDICINES ROFECOXIB/CELECOXIB: -- GI adverse effects ...................................................................... 4 HRT -- CPMP to re-evaluate risk-benefit ................................................................................ 4 LEVETIRACETAM & LOPINAVIR/RITONAVIR -- Potential for dispensing errors ............................. 4 MEFLOQUINE HYDROCHLORIDE -- Issuance of medication guide for travellers ........................... 4 REPAGLINIDE & GEMFIBROZIL -- Risk of hypoglycaemia with concomitant use .......................... 4 SALMETEROL -- New safety information for use in asthma....................................................... 5 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) -- Adverse effects in neonates ............. 5 VENLAFAXINE -- Unfavourable risk/benefit ratio for use in children and adolescents ................... 5 DRUGS OF INTEREST HMG-CoA Reductase Inhibitors and Ocular Haemorrhage......................................................... 7 FEATURE Safety Issues Involving Herbal Medicines: Kava as a Case Study.............................................. 8 MISCELLANY Recommendations from 1st Meeting of the Advisory Committee on Safety of Medicinal Products,20-22 October 2003, Geneva ................................................................. 10 REGULATORY MATTERS ASTEMIZOLE progression in patients with prevention of allograft rejection, localised prostate cancer in which 434 cardiac transplant Withdrawn due to otherwise managed by watchful recipients received concomitant ventricular waiting, AstraZeneca has cyclosporin, mycophenolate arrhythmias recommended that bicalutamide mofetil and corticosteroids. In 150mg be discontinued in such the study, increased mortality Argentina. As of 19 August patients. Patients taking was seen at 6 and 12 months in 2003, the Food, Drug and bicalutamide 50 mg/day for patients receiving daclizumab Medical Devices agency in metastatic prostate cancer are (Zenapax) compared with those Argentina, ANMAT, has not affected by this new receiving placebo (7% vs 5% (1) withdrawn all medicinal products information . The Committee on and 10% vs 6%, respectively). containing astemizole since these Safety of Medicines in the UK has Some of the increased mortality products have the potential to advised that for patients with appeared to be related to a cause life-threatening ventricular localized prostate cancer, the higher incidence of severe arrhythmias. (See also WHO balanced risk benefit of infection. Other sections of the Pharmaceuticals Newsletter No bicalutamide is unfavourable and product (Zenapax) labelling 4, 1993; 7 & 8, 1999; 3, 2003). the product is no longer licensed affected by the addition of this for the treatment of this information have also been Reference: condition. Other approved uses updated. Current information Communication from ANMAT, 19 are not affected. Patients relating to the risk of Aug 2003. Available from URL: receiving bicalutamide for hypersensitivity reactions has http://www.anmat.gov.ar localized prostate cancer should also been added to the be reviewed at the earliest ‘Warnings’ section, which states BICALUTAMIDE opportunity and treatment that severe, acute (onset within discontinued(2). 24 hours) hypersensitivity Withdrawn due to reactions including anaphylaxis References: accelerated deaths have been observed both on 1. Health Canada Warnings and initial exposure and following re- Canada, UK. Following Advisories, 18 Aug 2003. exposure to the product. discussions with Health Canada, Available from URL: Permanent discontinuation of AstraZeneca has issued a `Dear http://www.hc-sc.gc.ca daclizumab is advised in the Health Care Professional' letter 2. Communication from the Committee on Safety of event of a severe hyper- recommending that, due to a Medicines, 28 Oct 2003. sensitivity reaction. trend towards accelerated Available from URL: deaths, clinicians discontinue use http://www.mhra.gov.uk Reports in WHO-file: Allergic of bicalutamide (Casodex) reaction 3, anaphylactoid reaction 2 150mg in patients with localised DACLIZUMAB Reference: prostate cancer otherwise ‘Dear Healthcare Professional’ letter managed by watchful waiting Warning about from Roche Pharmaceuticals, Aug (i.e., therapy initiated only if hypersensitivity 2003. Available from URL: signs or symptoms of disease http://www.fda.gov progression occur). Approval was reactions, increased granted in November 2002 for mortality in cardiac bicalutamide 150mg as transplant study DANAZOL immediate therapy in some Use restricted to USA. The US prescribing patients with localised prostate information for daclizumab second-line therapy in cancer for whom surgery or (Zenapax) has been updated to endometriosis radiation was inappropriate. include two new warning Health Canada has now UK. The use of danazol (Danol) statements regarding increased withdrawn this approval after has been restricted to second- mortality seen in a cardiac reviewing data from a planned line therapy in endometriosis and transplant study and second analysis of the Early benign fibrocystic breast disease, hypersensitivity reactions. Roche Prostate Cancer trial programme as a result of safety and risk- Pharmaceuticals has issued a that show a trend towards benefit assessments suggesting ‘Dear Healthcare Professional’ accelerated deaths in patients that it may increase the baseline letter informing prescribers of with localised prostate cancer risk of ovarian cancer in patients the updates. The addition of who received bicalutamide being treated for endometriosis. information to the ‘Warnings’ 150mg, compared with those The following indications have section of the product label who received placebo (196 been removed from the Danol regarding increased mortality [25.2%] deaths vs 174 [20.5%] Summary of Product Character- reflects the findings of a deaths; hazard ratio 1.23; 95% istics (SPC): gynaecomastia, randomised, double-blind, CI 1−1.5). Based on this data, pre-operative thinning of the placebo-controlled trial of along with the absence of factors endometrium prior to surgery, daclizumab (Zenapax) for the suggesting a high risk of disease dysfunctional uterine bleeding WHO Pharmaceuticals Newsletter No. 5, 2003 S 1 REGULATORY MATTERS presenting as menorrhagia to MOROCTOCOG discontinue the sale of control excessive blood loss and nefazodone (Serzone-5HT2), to control dysmenorrhoea, ALFA indicated for the symptomatic control of benign, multiple or Reports of lack of relief of depressive illness. This recurrent breast cysts in decision follows several reports conjunction
Load more

Recommended publications
  • Thalidomide Celgene Pregnancy Prevention Programme Information
    TCPPP Healthcare Professional Booklet Thalidomide Celgene ® Pregnancy Prevention Programme Information for Healthcare Professionals ® Prescribing or Dispensing Thalidomide Celgene Celgene representative contact details: AM Mangion Ltd, Regulatory Office, “Mangion Building”, New Street Off Valletta Road, Luqa. Phone: +356 239 76333 Fax: +356 239 76123 Email: [email protected] Medical Information queries: [email protected] 2014 © Celgene Corporation Page 1 of 19 RMP/THA/001/14-03/M TCPPP Healthcare Professional Booklet This booklet is intended for healthcare professionals involved in prescribing or dispensing Thalidomide Celgene ®, and contains information about: Preventing harm to unborn babies: If Thalidomide Celgene® is taken during pregnancy it can cause severe birth defects or death to an unborn baby. Other side effects of Thalidomide Celgene®: The most commonly observed adverse reactions associated with the use of Thalidomide Celgene® in combination with melphalan and prednisone are: neutropenia, leukopenia, constipation, somnolence, paraesthesia, peripheral neuropathy, anaemia, lymphopenia, thrombocytopenia, dizziness, dysaesthesia, tremor and peripheral oedema. Further information and recommended precautions can be found in the Thalidomide Celgene® Summary of Product Characteristics (SmPC). Thalidomide Celgene® Pregnancy Prevention Programme: This Programme is designed to make sure that unborn babies are not exposed to Thalidomide Celgene®. It will provide you with information about how to follow the programme and explain your responsibilities. This booklet will help you understand these problems and make sure you know what to do before prescribing and dispensing Thalidomide Celgene®. For your patients’ own health and safety, please read this booklet carefully. You must ensure that your patients fully understand what you have told them about Thalidomide Celgene® before starting treatment.
    [Show full text]
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Outpatient Acne Care Guideline
    Outpatient Acne Care Guideline Severity Mild Moderate Severe < 20 comedones or < 20-100 comedones or 15-50 > 5 cysts, >100 comedones, or inflammatory lesions inflammatory lesions >50 inflammatory lesions Initial Treatment Initial Treatment Initial Treatment Benzoyl Peroxide (BP) or Topical Combination Therapy Combination Therapy Topical Retinoid Retinoid + BP Oral antibiotic or OR + (Retinoid + Antibiotic) + BP Topical retinoid Topical Combination Therapy or + BP + Antibiotic Retinoid + (BP + Antibiotic) or OR BP Retinoid + BP Oral antibiotic + topical retinoid + +/- or BP Topical antibiotic Retinoid + Antibiotic + BP or Topical Dapsone IF Inadequate Response IF Inadequate Response IF Inadequate Consider dermatology Response referral Change topical retinoid Consider changing oral concentrations, type and/or antibiotic formulation AND or Add BP or retinoid, if not already Change topiocal combination Consider isotretinoin prescribed therapy Consider hormone therapy or and/or (females) Change topical retinoid Add or change oral antibiotic concentrations, type and/or or formulation Consider isotretinoin Additional Considerations or Consider hormone therapy (females) Change topical comination Previous treatment/history Side effects therapy Costs Psychosocial impact Vehicle selection Active scarring Ease of use Regimen complexity Approved Evidence Based Medicine Committee 1-18-17 Reassess the appropriateness of Care Guidelines as condition changes. This guideline is a tool to aid clinical decision making. It is not a standard of care. The physician should deviate from the guideline when clinical judgment so indicates. GOAL: Pediatricians should initiate treatment for cases of “Mild” to “Severe” acne (see algorithms attached). Pediatricians should also counsel patients in order to maximize adherence to acne treatment regimens: 1. Realistic expectations. Patients should be counseled that topical therapies typically take up to 6-8 weeks to start seeing results.
    [Show full text]
  • Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration- Resistant Prostate Cancer Anna C
    Published OnlineFirst January 3, 2019; DOI: 10.1158/1078-0432.CCR-18-1589 Clinical Trials: Targeted Therapy Clinical Cancer Research Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration- Resistant Prostate Cancer Anna C. Ferrari1, Joshi J. Alumkal2, Mark N. Stein3, Mary-Ellen Taplin4, James Babb5, Ethan S. Barnett6, Alejandro Gomez-Pinillos5, Xiaomei Liu5, Dirk Moore6, Robert DiPaola7, and Tomasz M. Beer2 Abstract Purpose: This study assesses the action of panobino- Results: In the model, panobinostat/bicalutamide demon- stat, a histone deacetylase inhibitor (HDACI), in restor- strated synergistic antitumor effect while reducing AR activity. ing sensitivity to bicalutamide in a castration-resistant The dose-limiting toxicity was not reached. The probabilities of prostate cancer (CRPC) model and the efficacy and safety remaining rPF were 47.5% in the A arm and 38.5% in the B arm, of the panobinostat/bicalutamide combination in CRPC exceeding the protocol-specified threshold of 35%. The A arm patients resistant to second-line antiandrogen therapy but not the B arm exceeded expectations for times (medians) to (2ndLAARx). rP (33.9 and 10 weeks), and from PSA progression to rP (24 and Patients and Methods: The CWR22PC xenograft and 5.9 weeks). A arm/B arm events included: adverse events (AE), isogenic cell line were tested for drug interactions on 62%/19%; treatment stopped for AEs, 27.5%/11.5%; dose tumor cell growth and on the androgen receptor (AR), reduction required, 41%/4%. The principal A-arm grade 3 AR-splice variant7, and AR targets. A phase I trial had a AEs were thrombocytopenia (31%) and fatigue (14%).
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    Official Title: A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD- L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen NCT Number: NCT03016312 Document Date: Protocol Version 8: 14 February 2020 PROTOCOL TITLE: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTIPD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN PROTOCOL NUMBER: CO39385 VERSION NUMBER: 8 EUDRACT NUMBER: 2016-003092-22 IND NUMBER: 131196 TEST PRODUCTS: Atezolizumab (RO5541267) and enzalutamide MEDICAL MONITOR: , M.D., Ph.D. SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: Version 1: 29 September 2016 DATES AMENDED: Version 2: 7 March 2017 Version 3: 4 April 2017 Version 4: 29 June 2017 Version 5: 2 March 2018 Version 6: 23 August 2018 Version 7: 5 August 2019 Version 8: See electronic date stamp below. PROTOCOL AMENDMENT APPROVAL Date and Time (UTC) Title Approver's Name 14-Feb-2020 17:27:37 Company Signatory CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board.
    [Show full text]
  • Feminizing Hormone Therapy
    FEMINIZING HORMONE THERAPY Julie Thompson, PA-C Medical Director of Trans Health, Fenway Health April 2020 fenwayhealth.org GOALS AND OBJECTIVES 1. Review process of initiating hormone therapy through the informed consent model 2. Provide an overview of feminizing hormone therapy 3. Review realistic expectations and benefits of hormone therapy vs their associated risks 4. Discuss recommendations for monitoring fenwayhealth.org PROTOCOLS AND STANDARDS OF CARE fenwayhealth.org WPATH STANDARDS OF CARE, 2011 The criteria for hormone therapy are as follows: 1. Well-documented, persistent (at least 6mo) gender dysphoria 2. Capacity to make a fully informed decision and to consent for treatment 3. Age of majority in a given country 4. If significant medical or mental health concerns are present, they must be reasonably well controlled fenwayhealth.org INFORMED CONSENT MODEL ▪ Requires healthcare provider to ▪ Effectively communicate benefits, risks and alternatives of treatment to patient ▪ Assess that the patient is able to understand and consent to the treatment ▪ Informed consent model does not preclude mental health care! ▪ Recognizes that prescribing decision ultimately rests with clinical judgment of provider working together with the patient ▪ Recognizes patient autonomy and empowers self-agency ▪ Decreases barriers to medically necessary care fenwayhealth.org INITIAL VISITS ▪ Review history of gender experience and patient’s goals ▪ Document prior hormone use ▪ Assess appropriateness for gender affirming medical treatment ▪ WPATH criteria
    [Show full text]
  • Cancer Drug Pharmacology Table
    CANCER DRUG PHARMACOLOGY TABLE Cytotoxic Chemotherapy Drugs are classified according to the BC Cancer Drug Manual Monographs, unless otherwise specified (see asterisks). Subclassifications are in brackets where applicable. Alkylating Agents have reactive groups (usually alkyl) that attach to Antimetabolites are structural analogues of naturally occurring molecules DNA or RNA, leading to interruption in synthesis of DNA, RNA, or required for DNA and RNA synthesis. When substituted for the natural body proteins. substances, they disrupt DNA and RNA synthesis. bendamustine (nitrogen mustard) azacitidine (pyrimidine analogue) busulfan (alkyl sulfonate) capecitabine (pyrimidine analogue) carboplatin (platinum) cladribine (adenosine analogue) carmustine (nitrosurea) cytarabine (pyrimidine analogue) chlorambucil (nitrogen mustard) fludarabine (purine analogue) cisplatin (platinum) fluorouracil (pyrimidine analogue) cyclophosphamide (nitrogen mustard) gemcitabine (pyrimidine analogue) dacarbazine (triazine) mercaptopurine (purine analogue) estramustine (nitrogen mustard with 17-beta-estradiol) methotrexate (folate analogue) hydroxyurea pralatrexate (folate analogue) ifosfamide (nitrogen mustard) pemetrexed (folate analogue) lomustine (nitrosurea) pentostatin (purine analogue) mechlorethamine (nitrogen mustard) raltitrexed (folate analogue) melphalan (nitrogen mustard) thioguanine (purine analogue) oxaliplatin (platinum) trifluridine-tipiracil (pyrimidine analogue/thymidine phosphorylase procarbazine (triazine) inhibitor)
    [Show full text]
  • Adverse Effects in Women: Implications for Drug Development and Regulatory Policies
    Review For reprint orders, please contact [email protected] Adverse effects in women: implications for drug development and regulatory policies Expert Rev. Clin. Pharmacol. 4(4), 453–466 (2011) Ameeta Parekh†1, The requirement to establish safety of drugs prior to marketing has been in place since 1938 by Emmanuel O Fadiran1, the US Food, Drug and Cosmetic Act and is by no means a new concept. The efficacy regulations Kathleen Uhl2 were enacted in 1962 via the Kefauver–Harris Amendment and the drug approval process has and Douglas C evolved thereafter. The assessment of safety and efficacy of drug products is made by 2 pharmaceutical companies during drug development, which then goes through a regulatory Throckmorton review by the US FDA for the determination of market approval or nonapproval. The drug 1Food and Drug Administration, development and regulatory approval processes have endured close ongoing scrutiny by Office of Women’s Health, 10903 New Hampshire Avenue, regulatory bodies, the public, US Congress and academic and private organizations and, as a Silver Spring, MD 10993, USA result, have ensured continual refinement. Over the years, evidence has been emerging on varied 2Food and Drug Administration, drug responses in subgroup populations, and the underlying biology associated with age, race Center for Drug Evaluation and and sex as demographic variables have been examined. The resulting growing knowledge of Research, Office of Medical Policy, 10903 New Hampshire Avenue, disease burden, treatment response and disparate outcomes has generated opportunities to Silver Spring, MD 10993, USA streamline and improve treatment outcomes in these populations. This article discusses the †Author for correspondence: historical context of women’s participation in clinical drug trials submitted to the FDA for Tel.: +1 301 796 9445 regulatory review and approval purposes.
    [Show full text]
  • New Drugs Are Not Enough‑Drug Repositioning in Oncology: an Update
    INTERNATIONAL JOURNAL OF ONCOLOGY 56: 651-684, 2020 New drugs are not enough‑drug repositioning in oncology: An update ROMINA GABRIELA ARMANDO, DIEGO LUIS MENGUAL GÓMEZ and DANIEL EDUARDO GOMEZ Laboratory of Molecular Oncology, Science and Technology Department, National University of Quilmes, Bernal B1876, Argentina Received August 15, 2019; Accepted December 16, 2019 DOI: 10.3892/ijo.2020.4966 Abstract. Drug repositioning refers to the concept of discov- 17. Lithium ering novel clinical benefits of drugs that are already known 18. Metformin for use treating other diseases. The advantages of this are that 19. Niclosamide several important drug characteristics are already established 20. Nitroxoline (including efficacy, pharmacokinetics, pharmacodynamics and 21. Nonsteroidal anti‑inflammatory drugs toxicity), making the process of research for a putative drug 22. Phosphodiesterase-5 inhibitors quicker and less costly. Drug repositioning in oncology has 23. Pimozide received extensive focus. The present review summarizes the 24. Propranolol most prominent examples of drug repositioning for the treat- 25. Riluzole ment of cancer, taking into consideration their primary use, 26. Statins proposed anticancer mechanisms and current development 27. Thalidomide status. 28. Valproic acid 29. Verapamil 30. Zidovudine Contents 31. Concluding remarks 1. Introduction 2. Artesunate 1. Introduction 3. Auranofin 4. Benzimidazole derivatives In previous decades, a considerable amount of work has been 5. Chloroquine conducted in search of novel oncological therapies; however, 6. Chlorpromazine cancer remains one of the leading causes of death globally. 7. Clomipramine The creation of novel drugs requires large volumes of capital, 8. Desmopressin alongside extensive experimentation and testing, comprising 9. Digoxin the pioneer identification of identifiable targets and corrobora- 10.
    [Show full text]
  • Thalidomide and Pregnancy
    Thalidomide This sheet talks about exposure to thalidomide in pregnancy and while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider. What is thalidomide? Thalidomide is a sedative that also changes the body’s immune response and reduces the ability of the body to grow new blood vessels. Thalidomide was one of the first medications recognized to cause birth defects in humans. Thalidomide was not released in the United States until 1998. It has been used to treat several medical conditions, such as leprosy, certain types of cancer, inflammatory bowel disease and complications from HIV infection. It is sold under the brand name Thalomid®. I take thalidomide. Can it make it harder for me to get pregnant? There has been one small study that looked at women who had inflammatory bowel disease and were treated with thalidomide. This study suggested exposure to thalidomide might reduce the number of eggs in the ovaries. It is not clear if this would affect fertility. Further study is needed. Because thalidomide can cause birth defects when taken early in pregnancy, often before a woman recognizes that she is pregnant, it is very important that effective methods of birth control be used correctly and all of the time. It is recommended that two different and reliable methods of birth control be used if a woman is taking thalidomide. Thalidomide may decrease the effectiveness of oral contraceptives (birth control pills). The manufacturer developed the REMS (Risk Evaluation and Mitigation Strategy) program (formerly known as the S.T.E.P.S.® program) to help prevent exposure to pregnant women.
    [Show full text]